Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
The DOI matches its Crossref record, with a small difference in title or year; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ursodiol (ursodeoxycholic acid) therapy leads to major improvements in patients with primary biliary cirrhosis. The benefit of long-term treatment is uncertain. METHODS: We randomly assigned 145 patients with biopsy-proved primary biliary cirrhosis to receive ursodiol (13 to 15 mg per kilogram of body weight per day) (72 patients) or placebo (73 patients). After two years of follow-up, because of the benefit from ursodiol, all patients completing the study received ursodiol in an open trial and were monitored for two more years. The end points in the assessment of efficacy were as follows: progression of disease, as defined by the presence of hyperbilirubinemia, variceal bleeding, ascites, or encephalopathy; liver transplantation or a referral for that procedure; and liver transplantation (or a referral) or death. RESULTS: Disease progressed significantly less frequently in the ursodiol group than in the placebo group (P < 0.002; relative risk, 0.28; 95 percent confidence interval, 0.12 to 0.63). The probability of liver transplantation or a referral for that procedure and the probability of transplantation or death were significantly lower in the group assigned to ursodiol than in the group assigned to placebo (for transplantation alone, P = 0.003; relative risk, 0.21; 95 percent confidence interval, 0.07 to 0.66; for transplantation or death, P = 0.005; relative risk, 0.32; 95 percent confidence interval, 0.14 to 0.74). High bilirubin levels and, to a lesser extent, signs of cirrhosis at entry into the trial were predictive of disease progression, liver transplantation or a referral, and transplantation or death. CONCLUSIONS: Long-term ursodiol therapy slows the progression of primary biliary cirrhosis and reduces the need for liver transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Its use is already recommended for all patients with PBC by the American Association for the Study of Liver Diseases (AASLD) and EASL, as well as in this new guideline [35,[112][113][114][115][116][117][118][119][120][121].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [112]
In the citing paper
“Some studies with extended follow-up have also shown improved survival.(59,62,63)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [62]
In the citing paper
“while UDCA has proven beneficial effects in about 60% of PBC patients, it is less effective in PSC.(69)(70)(71)”
From The ascending pathophysiology of cholestatic liver disease (2017) · cites this paper as [70]
In the citing paper
“while UDCA has proven beneficial effects in about 60% of PBC patients, it is less effective in PSC.(69)(70)(71)”
From The ascending pathophysiology of cholestatic liver disease (2017) · cites this paper as [70]
Citations
Cites
1 retracted
Progression of primary biliary cirrhosis with ursodeoxycholic acid therapy
Perdigoto, R., & Wiesner, R. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)70038-d · Cited by 31
RetractedRegression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Self-citationStaging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
IS URSODEOXYCHOLIC ACID AN EFFECTIVE TREATMENT FOR PRIMARY BILIARY CIRRHOSIS?
Poupon, R., Poupon, R., Calmus, Y., Chrétien, Y., Ballet, F., & Darnis, F. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91610-2 · Cited by 536
Self-citationBeneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis
Christensen, E., Neuberger, J., Crowe, J., Altman, D. G., Popper, H., Portmann, B., Doniach, D., Ranek, L., Tygstrup, N., & Williams, R. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90213-6 · Cited by 423
Roll, J., Boyer, J. L., Barry, D., & Klatskin, G. (1983) · New England Journal of Medicine · doi:10.1056/nejm198301063080101 · Cited by 417
Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled double-blind trial
Leuschner, U., Fischer, H., Kurtz, W., Güldütuna, S., Hübner, K., Hellstern, A., Gatzen, M., & Leuschner, M. (1989) · Gastroenterology · doi:10.1016/0016-5085(89)91698-3 · Cited by 353
Research works printed but not linked: 5
- Triger DR, 1980, Gut, 21, A919
- Bassendine MF, 1982, Gut, 23, A909
- Lindor KD, 1992, Hepatology, 16, 91A
- Heathcote EJL, 1992, Hepatology, 16, 91A
- Goudie BM, 1989, Am J Gastroenterol, 84, 713
Cited by
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
“(141) A number of studies have shown the benefit of UDCA in this context.(58-63) Individual studies have demonstrated consistent evidence of improved liver biochemistries.”
BackgroundParés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
Metadata
- Authors
- Poupon, R. E., Poupon, R., & Balkau, B.
- Affiliations
- Inserm (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1994-05-12
- Volume
- 330
- Issue
- 19
- Pages
- 1342-1347
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2324587274
- Semantic Scholar
- ff372b99e1e9472b9e82b4f222254d165f3a5a4b
- Cited by
- 497
- References
- 35
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 18 · 2023: 6 · 2022: 8 · 2021: 10 · 2020: 12 · 2019: 19 · 2018: 18 · 2017: 14 · 2016: 12 · 2015: 16 · 2014: 15 · 2013: 9 · 2012: 10
- FWCI
- 23.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- ursodeoxycholic acid, primary biliary cirrhosis, long-term treatment, disease progression, liver transplantation, hyperbilirubinemia, variceal bleeding, ascites, encephalopathy, prognostic factors, bile acid therapy
- MeSH terms
- Double-Blind Method, Female, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Regression Analysis, Risk Factors, Ursodeoxycholic Acid, Liver Transplantation, Treatment Outcome, Liver Failure, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis. https://app.cochat.ai/papers/10.1056/nejm199405123301903
- The paper
- Poupon, R. E., Poupon, R., & Balkau, B. (1994). Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis. New England Journal of Medicine. https://doi.org/10.1056/nejm199405123301903
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.